Executive Vice President and Chief Medical Officer · Seres Therapeutics, Inc. (MCRB)

Lisa von Moltke

A named executive officer of Seres Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,270,353

Salary $515,000Stock awards $39,188

FY2023: $1,571,141

2nd of 3 named executive officers at Seres Therapeutics by FY2024 total.

3 named officers on file for Seres Therapeutics, FY2024

Lisa von Moltke’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • MCRB’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Seres Therapeutics’s whole pay program stands against its peers

  • Seres Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MCRB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 13, 2025 (DEF 14A).

Free

Get Lisa von Moltke’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Lisa von Moltke compensation by year

Seres Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Seres Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$515,000$515,000
Bonus$0$0
Stock awards$412,440$39,188
Option awards$433,552$502,178
Non-equity incentive$201,880$206,000
Pension and deferred compensation$0$0
All other$8,269$7,988
Total$1,571,141$1,270,353

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Seres Therapeutics, Inc. DEF 14A filed March 13, 2025, accession 0000950170-25-038441, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Seres Therapeutics, Inc. filed document, accession 0000950170-25-038441. Every figure is read from that document and cited to the page and table it appears in. Filed March 13, 2025.

$1.6M
$1.3M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU35,625$29,604—
RSU26,719$22,203—
Option54,688—$7.38
Option53,438—$5.50
Option6,875—$26.34
Option213,750—$1.10
Option287,905—$1.10

Per the Outstanding Equity Awards at Fiscal Year-End table in Seres Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Seres Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Eric ShaffFormer President and Chief Executive Officer$2,682,007
Lisa von Moltke · this pageExecutive Vice President and Chief Medical Officer$1,270,353
Thomas DesRosierExecutive Vice President & Chief Legal Officer$1,248,507

The full Seres Therapeutics compensation record

free company brief

This page is one person within Seres Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Seres Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lisa von Moltke's compensation dossier · One-time report. No refunds.